Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.

@article{Suppa2016PerformanceOH,
  title={Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.},
  author={Per Suppa and Harald Hampel and Timo Kepp and Catharina Lange and Lothar Spies and Jochen B. Fiebach and Bruno Dubois and Ralph Buchert},
  journal={Journal of Alzheimer's disease : JAD},
  year={2016},
  volume={51 3},
  pages={
          867-73
        }
}
MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease… 

Figures and Tables from this paper

Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease.
TLDR
The impact of intra-scanner test-retest and inter-field strength variability of FIRST-HV on clinical tasks is negligible and it is suggested that the additional variability encountered in the inter- field strength scenario does not cause a relevant degradation of FIRST's prognostic performance in MCI.
Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer’s disease: protocol for a rapid systematic review
TLDR
The extent of the evidence underlying the prediction of conversion to AD dementia from its early stage will be established and will provide a rigorous and updated synthesis of neuroimaging modalities allied with the data analysis techniques used to measure the brain changes during the conversion process.
Fractional Anisotropy changes in Parahippocampal Cingulum due to Alzheimer’s Disease
TLDR
A voxel-based analysis of fractional anisotropy in three classes of subjects suggests that pattern classification of Diffusion Tensor Imaging can help diagnosis of Alzheimer's disease, specially when focusing on the parahippocampal cingulum.
Hippocampal Volumes in Amnestic and Non-Amnestic Mild Cognitive Impairment Types Using Two Common Methods of MCI Classification
TLDR
Evidence of correlated neuroanatomical changes associated with memory performance for two commonly used neuropsychological MCI classification criteria is provided and clinical utility of hippocampal volumes analyzed via Neuroreader™ in MCI is investigated.
Prediction of Cognitive Decline in Temporal Lobe Epilepsy and Mild Cognitive Impairment by EEG, MRI, and Neuropsychology
TLDR
Combining information from EEG, MRI, and neuropsychology in order to predict neuropsychological changes in a heterogeneous population could create a more general model of cognitive performance decline.
Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study.
TLDR
Results suggested that increased serum miR-206 level might be a potential predictor of conversion from aMCI to AD.
The anteroposterior and primary-to-posterior limbic ratios as MRI-derived volumetric markers of Alzheimer's disease
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort.
TLDR
Hippocampal volume computed with the fully-automated processing pipeline provides similar power for prediction of MCI to probable AD conversion as computationally more expensive methods.
Fully automated atlas-based hippocampal volumetry for detection of Alzheimer's disease in a memory clinic setting.
TLDR
Evaluated fully automated atlas-based hippocampal volumetry fulfills the requirements for a relevant core feasible biomarker for detection of AD in everyday patient care in a secondary care memory clinic for outpatients.
Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging
TLDR
A US FDA cleared software program, NeuroreaderTM, is described and validation of a software program that can be applied in measuring hippocampal volume, a biomarker that is frequently abnormal in AD and other neurological disorders.
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
TLDR
Criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD, has four levels of certainty, depending on the presence and nature of the biomarker findings.
...
...